Alvotech Registered Shs Aktie
WKN DE: A3DK8U / ISIN: LU2458332611
|
05.05.2025 14:31:29
|
Teva Pharma, Alvotech Announce FDA Approval For SELARSDI
(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Alvotech (ALVO) announced the FDA has approved SELARSDI injection as interchangeable with the reference biologic Stelara or ustekinumab. As of April 30, 2025, SELARSDI is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohns disease, and ulcerative colitis.
In August 2020, Teva and Alvotech entered into a partnership for the commercialization of five Alvotech biosimilar product candidates, and in July 2023, the partnership was extended to include two additional biosimilars and new presentations of two previously partnered products. Alvotech manages development and manufacturing, while Teva is responsible for the exclusive commercialization in the U.S.
For More Such Health News, visit rttnews.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Alvotech Registered Shsmehr Nachrichten
|
06.05.25 |
Ausblick: Alvotech Registered präsentiert Quartalsergebnisse (finanzen.net) | |
|
22.04.25 |
Erste Schätzungen: Alvotech Registered legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) |
Analysen zu Alvotech Registered Shsmehr Analysen
Aktien in diesem Artikel
| Alvotech Registered Shs | 9,80 | 0,62% |
|
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 15,50 | -6,06% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.